Motley Fool Press Release.
Detailed price information for Dogwood Therapeutics Inc (DWTX-Q) from The Globe and Mail including charting and trades.
Moby summary of Talphera, Inc.'s Q2 2026 earnings call
Talphera (NASDAQ:TLPH) said it had reached 75% enrollment in its NEPHRO-CRRT registrational study and remains on track to complete enrollment later in 2026, as the company prepares for a potential commercial launch of its nafamostat anticoagulant candidate for continuous renal replacement therapy, o
Motley Fool Press Release.
Talphera: Q2 Earnings Snapshot
This is the newest page. Registered accounts read further back.